EYENEYENOVIA, INC.

Nasdaq eyenovia.com


$ 0.72 $ 0.04 (6.34 %)    

Wednesday, 29-May-2024 10:49:34 EDT
QQQ $ 454.82 $ 2.12 (0.47 %)
DIA $ 398.57 $ -0.14 (-0.04 %)
SPY $ 530.36 $ 1.34 (0.25 %)
TLT $ 91.26 $ -0.34 (-0.38 %)
GLD $ 225.37 $ 0.65 (0.3 %)
$ 0.6942
$ 0.68
$ 0.70 x 200
$ 0.00 x 0
$ 0.68 - $ 0.72
$ 0.50 - $ 3.17
409,464
na
32.35M
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-27-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-eyenovia-maintains-12-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.

 eyenovia-provides-updates-on-its-myopia-phase-iii-program-and-its-2-fda-approved-commercial-products-mydcombi-and-clobetasol

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric pro...

 eyenovia-q1-2024-gaap-eps-023-misses-017-estimate-sales-4993k-miss-816667k-estimate

Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by...

 eyenovia-provides-clinical-and-scientific-update-on-fda-approved-products-mydcombi-and-clobetasol-propionate-ophthalmic-suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest ...

 eyenovia-initiates-process-to-explore-strategic-alternatives-to-maximize-shareholder-value

The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progre...

 over-2m-bet-on-nextnav-check-out-these-3-penny-stocks-insiders-are-aggressively-buying

The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their co...

 hc-wainwright--co-reiterates-buy-on-eyenovia-maintains-12-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.

 recap-eyenovia-q4-earnings
Recap: Eyenovia Q4 Earnings
03/18/2024 20:30:15

 eyenovia-q4-eps-018-misses-017-estimate-sales-259k-miss-13000k-estimate

Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by...

 earnings-scheduled-for-march-18-2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

 earnings-preview-for-eyenovia
Earnings Preview For Eyenovia
03/15/2024 15:01:00

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION